Empirical Fluoroquinolones versus Broad-Spectrum Beta-Lactams for Gram-Negative Bloodstream Infections in the Absence of Antimicrobial Resistance Risk Factors

ConclusionsIn the absence of antimicrobial resistance risk factors, fluoroquinolones provide an additional empirical treatment option to BSBL for GN-BSI. Shorter HLOS in the fluoroquinolone group may be due to earlier transition from intravenous to oral antimicrobial therapy.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research